The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

In patients with eosinophilic esophagitis, etrasimod led to sustained histologic and endoscopic improvement over a year, with symptom relief in those without prior dilation.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Eohilia is an oral corticosteroid. Here’s how it treats eosinophilic esophagitis.

Esocap AG aims to transform the treatment of eosinophilic esophagitis with its drug delivery technology, ESO-101, designed to increase mucosal contact time and drug deposition in the esophagus. Data ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGP ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Bladder wall thickening (BWT) is not a specific condition but an indication of the potential presence of another condition such as bladder outlet obstruction, inflammation, interstitial cystitis, and ...

Check out these effective treatments for eosinophilic esophagitis (EoE) including lifestyle changes, medications like proton pump inhibitors and steroids, procedures, and mental health strategies.

Learn about eosinophilic esophagitis (EoE) and its symptoms, including chronic cough, treatment options, and diagnosis methods.

Eligible patients were 1 to 11 years of age with a documented diagnosis of active eosinophilic esophagitis (peak esophageal intraepithelial eosinophil count of ≥15 per high-power field in at ...